Pulmonary Oncology at Shanghai Pulmonary Hospital | CMCS

China's National Leader in Lung Cancer Medical Oncology

The Department of Pulmonary Oncology at Shanghai Pulmonary Hospital — affiliated with Tongji University — is one of China's most distinguished and nationally recognized lung cancer oncology centers, with a national reputation for excellence in targeted therapy, immunotherapy, chemotherapy, and the management of all stages of lung cancer. As one of China's highest-volume lung cancer centers, the department combines outstanding clinical expertise with a world-class clinical trials program, offering international patients access to some of China's most eminent lung cancer oncologists and the latest approved and investigational therapies. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their lung cancer treatment journey at Shanghai Pulmonary Hospital.

About the Department

The pulmonary oncology department is a national key clinical specialty operating dedicated oncology inpatient wards, a comprehensive outpatient lung cancer clinic, a chemotherapy and immunotherapy day unit, a molecular diagnostics laboratory with comprehensive NGS profiling, a clinical trials unit with access to phase I-III trials, and works in close collaboration with thoracic surgery, radiation oncology, interventional pulmonology, and pathology through a fully integrated multidisciplinary lung cancer tumor board meeting weekly.

Faculty members publish regularly in leading oncology journals including Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer, Cancer, and Thorax.

Non-Small Cell Lung Cancer (NSCLC)

Molecular Profiling & Biomarker Testing

Comprehensive molecular profiling is the cornerstone of lung cancer treatment at Shanghai Pulmonary Hospital:

• Next-Generation Sequencing (NGS) — Comprehensive tissue and liquid biopsy NGS panel; EGFR (exons 18-21, including uncommon mutations); ALK; ROS1; KRAS G12C; KRAS G12D; MET exon 14 skipping; MET amplification; BRAF V600E; RET; NTRK1/2/3; HER2 (ERBB2) exon 20 insertion; NRG1 fusion; FGFR; one of China's most comprehensive molecular profiling programs
• PD-L1 Testing — 22C3 (Dako); SP263 (Ventana); 28-8; TPS and CPS scoring; tumor mutational burden (TMB)
• Liquid Biopsy (ctDNA) — Plasma cfDNA NGS for treatment monitoring; resistance mechanism identification; T790M testing; MET amplification; C797S; osimertinib resistance profiling
• MET IHC — MET protein overexpression (3+) for telisotuzumab vedotin eligibility

EGFR-Mutated NSCLC

• First-Line — Osimertinib (Tagrisso) for common EGFR mutations (exon 19 del, L858R) — FLAURA trial; osimertinib + chemotherapy (FLAURA2 trial) for improved PFS; amivantamab + lazertinib (MARIPOSA trial) for exon 19 del and L858R
• Uncommon EGFR Mutations — Afatinib for G719X, S768I, L861Q; osimertinib for exon 20 insertions (selected); mobocertinib for exon 20 insertions; amivantamab for exon 20 insertions (CHRYSALIS trial)
• Osimertinib Resistance — T790M acquired resistance: osimertinib remains active; C797S: switch to first/second-gen TKI; MET amplification: osimertinib + savolitinib or tepotinib; HER2 amplification: trastuzumab deruxtecan; SCLC transformation: platinum + etoposide; histological transformation biopsy
• CNS Metastases — Osimertinib for CNS metastases (superior CNS penetration); SRS for oligometastatic CNS disease; WBRT with hippocampal avoidance for multiple metastases

ALK-Positive NSCLC

• First-Line — Alectinib (ALEX trial); brigatinib (ALTA-1L trial); lorlatinib (CROWN trial — superior PFS and CNS control); ensartinib
• Resistance — Lorlatinib for alectinib/brigatinib resistance; compound ALK mutations; repotrectinib for ROS1/NTRK/ALK; next-generation sequencing for resistance mechanism

KRAS G12C NSCLC

• Sotorasib — CodeBreaK 200 trial; second-line after platinum + immunotherapy
• Adagrasib — KRYSTAL-1 trial; CNS activity; adagrasib + cetuximab for KRAS G12C colorectal cancer
• KRAS G12D — MRTX1133; investigational; clinical trial access

MET-Altered NSCLC

• MET Exon 14 Skipping — Tepotinib (VISION trial); capmatinib (GEOMETRY mono-1); savolitinib; one of China's most experienced MET exon 14 programs
• MET Amplification — Savolitinib + osimertinib for MET-amplified osimertinib-resistant NSCLC (SAVANNAH trial); tepotinib + osimertinib (INSIGHT 2)
• Telisotuzumab Vedotin — MET-overexpressing (IHC 3+) NSCLC; ADC targeting MET; TeliADC trial

RET-Rearranged NSCLC

• Selpercatinib (LIBRETTO-001); pralsetinib (ARROW trial); superior CNS activity; one of China's most experienced RET fusion programs

BRAF V600E NSCLC

• Dabrafenib + trametinib (GEOMETRY-D); one of China's most experienced BRAF V600E NSCLC programs

HER2-Mutated NSCLC

• Trastuzumab deruxtecan (T-DXd — DESTINY-Lung02); poziotinib; pyrotinib for HER2 exon 20 insertions; one of China's most experienced HER2-mutated NSCLC programs

NTRK-Fusion NSCLC

• Larotrectinib (LOXO-TRK); entrectinib; repotrectinib for TRK inhibitor-resistant disease

NRG1-Fusion NSCLC

• Zenocutuzumab (bispecific HER2 x HER3); afatinib; pertuzumab + trastuzumab; investigational agents

Immunotherapy for NSCLC

• PD-L1 ≥50% (First-Line Monotherapy) — Pembrolizumab (KEYNOTE-024); cemiplimab (EMPOWER-Lung 1); atezolizumab; sintilimab; camrelizumab
• Combination Immunotherapy + Chemotherapy — Pembrolizumab + carboplatin + pemetrexed (KEYNOTE-189 for non-squamous); pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel (KEYNOTE-407 for squamous); atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP — IMpower150); nivolumab + ipilimumab + chemotherapy (CheckMate 9LA)
• Dual Checkpoint Blockade — Nivolumab + ipilimumab (CheckMate 227 for TMB-high or PD-L1 ≥1%); durvalumab + tremelimumab (POSEIDON)
• Stage III Unresectable NSCLC — Concurrent chemoradiation + durvalumab consolidation (PACIFIC trial); osimertinib for EGFR-mutated stage III after CRT (LAURA trial)
• irAE Management — Immune-related pneumonitis; colitis; hepatitis; endocrinopathies; myocarditis; corticosteroids; infliximab; vedolizumab for refractory colitis

Antibody-Drug Conjugates (ADCs) for NSCLC

• Trastuzumab Deruxtecan (T-DXd) — HER2-mutated NSCLC (DESTINY-Lung02); HER2-overexpressing NSCLC
• Datopotamab Deruxtecan (Dato-DXd) — TROP2-targeting ADC; TROPION-Lung01 for pre-treated NSCLC; TROPION-Lung08 first-line combination
• Telisotuzumab Vedotin — MET-overexpressing NSCLC
• Patritumab Deruxtecan (HER3-DXd) — HER3-expressing NSCLC; HERTHENA-Lung01; post-EGFR TKI

Small Cell Lung Cancer (SCLC)

• Extensive-Stage SCLC (ES-SCLC) — Atezolizumab + carboplatin + etoposide (IMpower133); durvalumab + carboplatin + etoposide (CASPIAN); sintilimab + chemotherapy; serplulimab + chemotherapy (ASTRUM-005)
• Relapsed SCLC — Tarlatamab (DLL3 x CD3 BiTE — DeLLphi-301); lurbinectedin; topotecan; amrubicin; nivolumab; pembrolizumab for TMB-high
• Limited-Stage SCLC (LS-SCLC) — Concurrent chemoradiation; prophylactic cranial irradiation (PCI) vs. MRI surveillance; durvalumab consolidation (ADRIATIC trial)
• SCLC Molecular Subtypes — SCLC-A (ASCL1); SCLC-N (NEUROD1); SCLC-P (POU2F3); SCLC-I (YAP1); subtype-directed therapy; ONC201 for SCLC

Mesothelioma

• Unresectable MPM — Nivolumab + ipilimumab (CheckMate 743 — superior to chemotherapy); pembrolizumab; cisplatin + pemetrexed + bevacizumab; BAP1 and NF2 mutation testing
• Resectable MPM — Multimodality therapy; coordination with thoracic surgery for P/D or EPP; IMRT coordination

Clinical Trials

Shanghai Pulmonary Hospital's clinical trials program is one of China's most active in lung cancer:

• Phase I-III trials for novel targeted agents, immunotherapy combinations, and ADCs
• Investigator-initiated trials (IITs) for rare driver mutations
• Biomarker-driven basket trials
• Access to pre-approval agents for patients with no standard treatment options
• CMCS facilitates clinical trial eligibility screening and enrollment coordination for international patients

Why International Patients Choose Shanghai Pulmonary Hospital Pulmonary Oncology

• China's Highest-Volume Lung Cancer Center — Unparalleled clinical experience; one of the world's most experienced lung cancer oncology programs
• Comprehensive Molecular Profiling — Full NGS panel including rare drivers; liquid biopsy; resistance mechanism profiling
• Amivantamab + Lazertinib — MARIPOSA regimen for EGFR-mutated NSCLC; superior PFS vs. osimertinib monotherapy
• Tarlatamab for SCLC — DLL3-targeted BiTE for relapsed SCLC; DeLLphi-301 evidence
• ADC Expertise — T-DXd, Dato-DXd, HER3-DXd, telisotuzumab vedotin; comprehensive ADC program
• Clinical Trial Access — One of China's most active lung cancer clinical trials programs; access to pre-approval agents
• Cost-Effectiveness — World-class lung cancer care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your lung cancer diagnosis, pathology reports, molecular profiling results (NGS, PD-L1), imaging (CT, PET-CT, brain MRI), and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate lung cancer oncologist based on your molecular profile and stage — EGFR, ALK, KRAS, MET, RET, HER2, immunotherapy, or SCLC specialist.
4. MDT Submission — We facilitate pre-arrival case review by the multidisciplinary lung cancer tumor board.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accommodation near Shanghai Pulmonary Hospital, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of targeted therapy initiation, immunotherapy infusion scheduling, chemotherapy, or clinical trial enrollment.
8. Post-Treatment Follow-Up — Treatment report translation, response assessment coordination, resistance biopsy coordination, and remote follow-up after you return home.

Book a Consultation

If you have non-small cell lung cancer, small cell lung cancer, mesothelioma, or any thoracic malignancy — CMCS can arrange a specialist consultation with Shanghai Pulmonary Hospital's world-leading pulmonary oncology team.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com